Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
Key facts
- Where
- 's-Gravenhage, 'S-Gravenhage, 'S-Hertogenbosch, Alkmaar, Almere, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Breda, Delft, Deventer, Dordrecht, Eindhoven, Enschede, Groningen, Haarlem, Heerlen, Helmond, Leeuwarden, Leiden, Leiderdorp, Maastricht, Nieuwegein, Nijmegen, Rotterdam, Tiel, Tilburg, Uden, Utrecht, Venlo és Zwolle, HollandiaSee the 37 sites
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- Haga Hospital's-Gravenhage, HollandiaTaking people
- Haaglanden Medisch Centrum Stichting'S-Gravenhage, HollandiaTaking people
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, HollandiaTaking people
- Noordwest Ziekenhuisgroep StichtingAlkmaar, HollandiaTaking people
- Flevoziekenhuis StichtingAlmere, HollandiaTaking people
- Meander Medisch CentrumAmersfoort, HollandiaTaking people
- Academisch Medisch CentrumAmsterdam, HollandiaTaking people
- Stichting OLVGAmsterdam, HollandiaTaking people
- Gelre HospitalsApeldoorn, HollandiaTaking people
- Rijnstate Ziekenhuis StichtingArnhem, HollandiaTaking people
- Amphia HospitalBreda, HollandiaTaking people
- Reinier de Graaf GroepDelft, HollandiaTaking people
- Deventer ZiekenhuisDeventer, HollandiaTaking people
- Albert Schweitzer ZiekenhuisDordrecht, HollandiaTaking people
- Catharina Ziekenhuis StichtingEindhoven, HollandiaTaking people
- Medisch Spectrum TwenteEnschede, HollandiaTaking people
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
- Spaarne Gasthuis StichtingHaarlem, HollandiaTaking people
- Zuyderland Medisch Centrum StichtingHeerlen, HollandiaTaking people
- Elkerliek ziekenhuisHelmond, HollandiaTaking people
- Medisch Centrum Leeuwarden B.V.Leeuwarden, HollandiaTaking people
- Leids Universitair Medisch Centrum (LUMC)Leiden, HollandiaTaking people
- Alrijne Zorggroep StichtingLeiderdorp, HollandiaTaking people
- Universiteit MaastrichtMaastricht, HollandiaTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, HollandiaTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, HollandiaTaking people
- Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, HollandiaTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaTaking people
- Maasstad Ziekenhuis StichtingRotterdam, HollandiaTaking people
- Sint Franciscus Vlietland Groep StichtingRotterdam, HollandiaTaking people
- Ziekenhuis RivierenlandTiel, HollandiaTaking people
- Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, HollandiaTaking people
- Bernhoven B.V.Uden, HollandiaTaking people
- Diakonessenhuis StichtingUtrecht, HollandiaTaking people
- Universitair Medisch Centrum UtrechtUtrecht, HollandiaTaking people
- Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, HollandiaTaking people
- Isala Klinieken StichtingZwolle, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting Radboud universitair medisch centrum
- Trial code
- EU 2024-513092-40-00
- Record updated
- 2026. október 21.
- Original description
To investigate whether discontinuation of antiplatelet therapy is non-inferior to continuation of antiplatelet therapy, to prevent major cardiovascular events three to ten years after cryptogenic TIA or ischaemic stroke at young age.Read full original descriptionShow less
Stopping or continuing platelet inhibitors after cryptogenic stroke at young age: STOP trial
To investigate whether discontinuation of antiplatelet therapy is non-inferior to continuation of antiplatelet therapy, to prevent major cardiovascular events three to ten years after cryptogenic TIA or ischaemic stroke at young age.
Inclusion: First ever ischaemic stroke, or TIA with evidence of ischaemia on imaging, 3-10 years prior to study participation; Age 18-49 years at the time of TIA/ischaemic stroke; Cryptogenic aetiology, defined as no other aetiology after standard work-up according to national and international guidelines for young stroke (imaging of the brain (CT-scan or MRI-scan) and cervical arteries (CTA, MRA or carotid ultrasound), routine blood tests (complete blood count, erythrocyte sedimentation rate, CRP, antiphospholipid antibodies), ECG, at least 24 hours cardiac rhythm monitoring and transthoracic/transesophageal echocardiography).
Exclusion: Other indication for antiplatelet therapy; History of MI, coronary revascularisation or documented peripheral arterial disease; Any stenosis of intracranial or cervical artery at time of stroke; Any condition that prevents long-term follow-up; Two or more risk factors for atherosclerotic disease according to the following definitions: • arterial hypertension (treated or known blood pressure before stroke >140/90 mm Hg) • diabetes mellitus (treated or known blood fasting glucose >7 mmol/l) • current smoking (or smoking stopped within the last 6 months), • hypercholesterolaemia (treated or known low-density lipoprotein before the stroke >160 mg/dl or 4, mmol/l); Indication for oral anticoagulants or low molecular weight heparin; Recurrent ischaemic event at any time after the index event.